Alphatec is the top performing healthcare equipment stock YTD
Seeking Alpha News (Mon, 22-Dec 12:12 PM ET)
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
Business Wire (Wed, 17-Dec 8:00 AM ET)
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform
Business Wire (Thu, 11-Dec 8:00 AM ET)
AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference
Business Wire (Tue, 18-Nov 8:00 AM ET)
AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025
Business Wire (Wed, 29-Oct 4:01 PM ET)
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial
Business Wire (Tue, 28-Oct 8:00 AM ET)
AtriCure to Participate in Upcoming Investor Conferences
Business Wire (Mon, 27-Oct 8:00 AM ET)
AtriCure to Announce Third Quarter 2025 Financial Results
Business Wire (Wed, 8-Oct 8:00 AM ET)
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Atricure trades on the NASDAQ stock market under the symbol ATRC.
As of December 26, 2025, ATRC stock price declined to $40.33 with 116,410 million shares trading.
ATRC has a beta of 0.60, meaning it tends to be less sensitive to market movements. ATRC has a correlation of 0.06 to the broad based SPY ETF.
ATRC has a market cap of $2.00 billion. This is considered a Mid Cap stock.
Last quarter Atricure reported $134 million in Revenue and -$.01 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.10.
In the last 3 years, ATRC traded as high as $59.61 and as low as $18.94.
The top ETF exchange traded funds that ATRC belongs to (by Net Assets): VTI, IWM, VB, VBK, VXF.
ATRC has outperformed the market in the last year with a return of +32.2%, while the SPY ETF gained +16.0%. In the last 3 month period, ATRC beat the market returning +11.7%, while SPY returned +4.7%. However, in the most recent 2 weeks ATRC has underperformed the stock market by returning -2.1%, while SPY returned +0.7%.
ATRC support price is $39.33 and resistance is $41.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATRC shares will trade within this expected range on the day.